醫療科技評估報告 | 合法藥品大搜索

修訂後給付規定. 原給付規定. 8.2.4.6.Etanercept（如Enbrel）；adalimumab（如Humira）；ustekinumab（如Stelara）；secukinumab（ ... Read More

本案藥品Skyrizi (risankizumab)為一種人類免疫球蛋白G1 (IgG1)單株抗體，. 會與IL-23 細胞激素的p19 次單元以高度親和力選擇性結合，並抑制其與IL-23. 受體複合體 ... Read More

Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie. Risankizumab has been approved in the European Union, the United States, ... Read More

Risankizumab (ABBV-066) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease,​ ... Read More

Risankizumab is a biological treatment used for psoriasis, a skin disorder in which skin cells form scaly red plaques, commonly found on the elbows, knees, and ... Read More

【公文】公告暫予支付含risankizumab成分（如Skyrizi）藥品支付價格及其藥品給付規定。 由NTPA012 在2020, 十一月23 - 16:02 發表. 發表於. 中央健康保險署 ... Read More

Indication. SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Read More

由 A Blauvelt 著作 · 2020 · 被引用 33 次 — Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that binds with high affinity to the p19 subunit and selectively inhibits IL- ... Read More

2021年1月7日 — Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction ... Read More